FILING ANALYSIS · WEDNESDAY, NOVEMBER 4
BIO-RAD LABORATORIES, INC. BIO — 8-K: Results of Operations and Financial Condition
neutral
Bio-Rad reported a net income of $458.6 million, or $17.02 per share, driven by a change in the fair market value of its investment in Sartorius AG, but non-GAAP income per diluted share was $2.65, and the company maintained its full-year 2026 financial outlook, expecting non-GAAP, currency-neutral revenue to be in the range of a decline of approximately 3.0 percent to growth of approximately 0.5
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →